Home › Funds › CONGRESS ASSET MANAGEMENT CO › TGTX
CONGRESS ASSET MANAGEMENT CO position in TGTX
TG THERAPEUTICS · Health Care
CONGRESS ASSET MANAGEMENT CO reported holding 2,606,516 shares of TGTX (TG THERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$145.4M, representing 0.95% of its reported portfolio and ranking #23 among its reported holdings. CONGRESS ASSET MANAGEMENT CO has disclosed TGTX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-10-09 · Source: SEC EDGAR Form 13F-HR
How CONGRESS ASSET MANAGEMENT CO's TGTX position evolved
CONGRESS ASSET MANAGEMENT CO first disclosed a stake in TGTX in Q4 2025 at 1,922,410 shares (US$57.3M). The position peaked in Q3 2026 at 2,606,516 shares, worth US$145.4M. Across 4 filings, CONGRESS ASSET MANAGEMENT CO increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 2,606,516 shares valued at US$145.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.92M | $57.31M | New |
| Q1 2026 | 2.17M | $72.02M | Add |
| Q2 2026 | 2.60M | $142.85M | Add |
| Q3 2026 | 2.61M | $145.39M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TGTX and 13F data
TGTX (TG THERAPEUTICS) is a Health Care company. 52 other funds we track also report a position in TGTX — the largest reported positions include Soleus Capital Management, L.P. (US$160.9M), Penn Capital Management Company, LLC (US$29.5M), Opaleye Management Inc. (US$29.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TGTX
- Soleus Capital Management, L.P. 2.93M sh · $160.86M · Q2 2026
- Penn Capital Management Company, LLC 536.07K sh · $29.51M · Q2 2026
- Opaleye Management Inc. 535.00K sh · $29.39M · Q2 2026
- Occam Crest Management LP 425.00K sh · $22.73M · Q2 2026
- 683 Capital Management, LLC 389.08K sh · $21.38M · Q2 2026
More on CONGRESS ASSET MANAGEMENT CO
FAQ
How long has CONGRESS ASSET MANAGEMENT CO held TGTX?
CONGRESS ASSET MANAGEMENT CO has disclosed TGTX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is CONGRESS ASSET MANAGEMENT CO's current position in TGTX?
As of Q3 2026, CONGRESS ASSET MANAGEMENT CO holds 2.61M shares of TGTX (TG THERAPEUTICS), valued at $145.39M, representing 0.95% of its reported portfolio and ranking #23.
Has CONGRESS ASSET MANAGEMENT CO been buying or selling TGTX?
In the latest 13F filing (Q3 2026), CONGRESS ASSET MANAGEMENT CO held unchanged its position in TGTX. The position peaked in Q3 2026 at 2.61M shares.
Which other funds hold TGTX?
Other major institutional holders of TGTX include Soleus Capital Management, L.P., Penn Capital Management Company, LLC, Opaleye Management Inc., among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.